Literature DB >> 22560674

Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide.

Mohamed L Salem1, Amir A Al-Khami, Sabry A El-Nagaar, Abdel-Aziz A Zidan, Ismail M Al-Sharkawi, C Marcela Díaz-Montero, David J Cole.   

Abstract

Recently, we showed that post cyclophosphamide (CTX) microenvironment benefits the function of transferred T cells. Analysis of the kinetics of cellular recovery after CTX treatment showed that a single 4 mg/mouse CTX treatment decreased the absolute number of leukocytes in the peripheral blood (PBL) at days 3-15, and in the spleen and bone marrow (BM) at days 3-6. The absolute numbers of CD11c(+)CD11b(-) and CD11c(+)CD11b(+) dendritic cells (DCs), CD11b(+) and Ly6G(+) myeloid cells, T and B cells, CD4(+)CD25(+) T regulatory (T(reg)) cells, and NK1.1(+) cells also decreased. The cell numbers returned to control levels during the recovery phase. The absolute numbers of B cells remained low for 3 weeks. The numbers of DCs increased in PBL and spleen at day 9 but returned to control levels at day 15. These data indicate that CTX alters the cellular microenvironment in kinetics that might be precisely targeted to benefit the host.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560674      PMCID: PMC3787597          DOI: 10.1016/j.cellimm.2012.03.010

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  38 in total

1.  Differential effects of a single dose of cyclophosphamide on T cell subsets of the thymus and spleen in mice: flow cytofluorometry analysis.

Authors:  A Miyauchi; C Hiramine; S Tanaka; K Hojo
Journal:  Tohoku J Exp Med       Date:  1990-10       Impact factor: 1.848

2.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors:  E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

3.  Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.

Authors:  J E Gold; S D Ross; D J Krellenstein; F LaRosa; S C Malamud; M E Osband
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

4.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

5.  Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial.

Authors:  J S Abrams; J L Eiseman; T J Melink; R Sridhara; D J Hiponia; M M Bell; C P Belani; W H Adler; J Aisner
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-07

6.  Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.

Authors:  Ian F Hermans; Tsung Wen Chong; Michael J Palmowski; Adrian L Harris; Vincenzo Cerundolo
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

7.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Authors:  François Ghiringhelli; Nicolas Larmonier; Elise Schmitt; Arnaud Parcellier; Dominique Cathelin; Carmen Garrido; Bruno Chauffert; Eric Solary; Bernard Bonnotte; François Martin
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

8.  Anamnestic responses induced by antigen persisting on follicular dendritic cells from cyclophosphamide-treated mice.

Authors:  R P Phipps; T E Mandel; C T Schnizlein; J G Tew
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

9.  Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative.

Authors:  J Limpens; M Van Meijer; H M Van Santen; W T Germeraad; K Hoeben-Schornagel; M Breel; R J Scheper; G Kraal
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

10.  Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.

Authors:  Fiona J Radcliff; Denise A Caruso; Craig Koina; Marcia J Riordan; Andrew W Roberts; Mimi L K Tang; Charles M Baum; Susan L Woulfe; David M Ashley
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

View more
  14 in total

1.  Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells.

Authors:  Xiaoyun Lu; Zhi-Chun Ding; Yang Cao; Chufeng Liu; Tsadik Habtetsion; Miao Yu; Henrique Lemos; Huda Salman; Hongyan Xu; Andrew L Mellor; Gang Zhou
Journal:  J Immunol       Date:  2015-01-05       Impact factor: 5.422

2.  Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.

Authors:  J Wang; T R McGuire; H C Britton; J K Schwarz; F R Loberiza; J L Meza; J E Talmadge
Journal:  Clin Exp Metastasis       Date:  2015-01-25       Impact factor: 5.150

3.  [Therapeutic effect of Panax notoginseng saponins combined with cyclophosphamide in mice bearing hepatocellular carcinoma H22 cell xenograft].

Authors:  Q Zou; X Wu; J Wang; D Xia; M Deng; Y Ding; Y Dai; S Zhao; T Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

4.  A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome.

Authors:  Marianne Delville; Florence Bellier; Juliette Leon; Roman Klifa; Sabrina Lizot; Hélène Vinçon; Steicy Sobrino; Romane Thouenon; Armance Marchal; Alexandrine Garrigue; Juliette Olivré; Soëli Charbonnier; Chantal Lagresle-Peyrou; Mario Amendola; Axel Schambach; David Gross; Baptiste Lamarthée; Christophe Benoist; Julien Zuber; Isabelle André; Marina Cavazzana; Emmanuelle Six
Journal:  Blood       Date:  2021-04-29       Impact factor: 22.113

5.  Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.

Authors:  Genevieve M Weir; Olga Hrytsenko; Marianne M Stanford; Neil L Berinstein; Mohan Karkada; Robert S Liwski; Marc Mansour
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

6.  The protective effect of lemon fruit extract on histopathological changes induced in small intestines and pancreas of male mice by cyclophosphamide.

Authors:  Salwa Mohammed Quita; Samira Omar Balbaid
Journal:  Electron Physician       Date:  2015-10-19

7.  Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance.

Authors:  Xiaoyu Han; Yunfu Lv; Yejuan Li; Jie Deng; Qingan Qiu; Ning Liu; Shuya Zhao; Caixian Liao
Journal:  J Int Med Res       Date:  2018-05-20       Impact factor: 1.671

8.  Studies of the effects and mechanisms of ginsenoside Re and Rk3 on myelosuppression induced by cyclophosphamide.

Authors:  Jiahong Han; Jing Xia; Lianxue Zhang; Enbo Cai; Yan Zhao; Xuan Fei; Xiaohuan Jia; He Yang; Shuangli Liu
Journal:  J Ginseng Res       Date:  2018-08-30       Impact factor: 6.060

Review 9.  Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy.

Authors:  Patrick Innamarato; Shari Pilon-Thomas
Journal:  Cell Immunol       Date:  2020-12-26       Impact factor: 4.868

10.  Elevated granulocytic myeloid-derived suppressor cells are closely related with elevation of Th17 cells in mice with experimental asthma.

Authors:  Fei Xue; Mengzhu Yu; Li Li; Wenzhe Zhang; Yongbin Ma; Liyang Dong; Wenqi Shan; Yu Zheng; Ting Wang; Dingqi Feng; Jianping Lv; Xuefeng Wang
Journal:  Int J Biol Sci       Date:  2020-05-16       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.